Hoth Therapeutics, a biopharmaceutical company, has announced the request for a Pre-Investigational New Drug meeting to the FDA to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disorders associated with epidermal growth factor receptor (EGFR) inhibitor therapy. "Palliative care treatment for cancer patients continues to be an undeserved segement of the market that our HT-001 product has an opportunity to provide patients with a better quality of life during their cancer treatment", said Robb Knie, Chairman and CEO Of Hoth Therapeutics. ourway is delighted about the positive results and continues to support the fight against cancer. Yourway supports the fight against cancer.